Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R

Oncogene volume 21, pages 5047–5055 (2002)Cite this article

Abstract

To gain insight into the molecular basis of human prolactin (hPRL) antagonist induced apoptosis, we compared the differential gene expression profile of four human breast cancer cell lines following treatment with hPRL and its antagonist (hPRL-G129R). Among the genes identified, the bcl-2 gene was of particular interest. We found that bcl-2 mRNA was up regulated in three of the four cell lines that were treated with hPRL. To further confirm these results, real time RT–PCR and ELISA analyses were used to detect bcl-2 mRNA and Bcl-2 protein, respectively, in 11 different breast cancer cell lines after hPRL or hPRL-G129R treatment. Our data suggests that Bcl-2 is up-regulated in response to hPRL stimulation and is competitively inhibited by hPRL-G129R in the majority of the cell lines tested. Thus, we propose that the anti-apoptotic role of hPRL in breast cancer is mediated, at least in part, through regulation of Bcl-2.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Adams JM, Cory S . 1998 Science 281: 1322–1326

  • Beck MT, Holle L, Chen WY . 2001 Biotechniques 31: 782–786

  • Binder C, Marx D, Binder L, Schour A, Hiddemann W . 1996 Ann. Oncol. 7: 129–133

  • Blackwell RE, Hammond KR . 1999 Hormonal Control of Normal Breast Morphology and Function Manni A (ed) Humana Press: New Jersey pp. 3–20

    Google Scholar 

  • Chen G, Ray R, Dubik D, Shi L, Cizeau J, Bleackley RC, Saxena S, Gietz RD, Greenberg AH . 1997 J. Exp. Med. 186: 1975–1983

  • Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen WY . 2002 Int. J. Oncol. 20: 813–818

  • Chen WY, Ramamoorthy P, Chen NY, Sticca RP, Wagner TE . 1999 Clin. Cancer Res. 5: 3583–3593

  • Clevenger CV, Chang WP, Ngo W, Pashe TLM, Montone KT, Tomaszewski JE . 1995 Am. J. Pathol. 146: 695–705

  • DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM . 1996 Nat. Genet. 14: 457–460

  • Ginsburg E, Vonderhaar BK . 1995 Cancer Res. 55: 2591–2595

  • Goffin V, Kelly PA . 1997 J. Mammary Gland Biol. Neoplasia 2: 7–17

  • Goffin V, Kinet S, Ferrag F, Binart N, Martial JA, Kelly PA . 1996 J. Biol. Chem. 271: 16573–16579

  • Green DR . 2000 Cell 7: 1–4

  • Green DR, Beere HM . 1999 Apoptosis and Cancer Chemotherapy: Mechanisms of Apoptotis Hickman JA and Dive C (ed) Humana Press: New Jersey pp. 157–174

    Book  Google Scholar 

  • Guiliano D, Ganatra M, Ware J, Parrot J, Daub J, Moran L, Brennecke H, Foster JM, Supali T, Blaxter M, Scott AL, Williams SA, Slatko BE . 1999 Biotechniques 27: 1476–1482

  • Hakvoort TB, Leegwater AC, Michiels FA, Chamuleau RA, Lamers WH . 1994 Nucleic Acids Res. 22: 878–879

  • Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV . 1996 Immunity 4: 387–396

  • Janicke RU, Sprengart ML, Wati MR, Porter AG . 1998 J. Biol. Chem. 273: 9357–9360

  • Kelly PA, Djiane J, Postel-Vinay MC, Edery M . 1991 Endocr. Rev. 12: 235–251

  • Korsmeyer SJ . 1999 Cancer Res. 59: 1693–1700

  • Krumenacker JS, Buckley DJ, Leff MA, McCormack JT, de Jong G, Gout PW, Reed JC, Miyashita T, Magnuson NS, Buckley AR . 1998 Endocrine 2: 163–170

  • Kuang WW, Thompson DA, Hoch RV, Weigel RJ . 1998 Nucleic Acids Res. 26: 1116–1123

  • Kumar R, Vadlamundi RK, Adam L . 2000 Endocrin. Rel. Cancer 7: 257–269

  • Leff MA, Buckley DJ, Krumenacker JS, Reed JC, Miyashita T, Buckley AR . 1996 Endocrinology 12: 5456–5462

  • Li M . 1997 Proc. Natl. Acad. Sci. USA 94: 3425–3430

  • Liang Y, Yan C, Schor NF . 2001 Oncogene 4: 6570–6580

  • Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA, Goffin V . 2000 Oncogene 19: 4695–4705

  • Merino R, Ding L, Veis DJ, Korsmeyer SJ, Nunez G . 1994 EMBO J. 13: 683–691

  • Nagasawa H, Miur K, Niki K, Namiki H . 1985 Exp. Clin. Endocrinol. 86: 357–360

  • Oh JJ, Grosshans DR, Wong SG, Slamon DJ . 1999 Nucleic Acids Res. 27: 4008–4017

  • Ormandy CJ, Hall RE, Manning DL, Robertson JF, Blamey RW, Kelly PA, Nicholson RI, Sutherland RL . 1997 J. Clin. Endocrinol. Metab. 82: 3692–3699

  • Peirce SK, Chen WY . 2001 J. Endocrinol. 171: R1–R4

  • Ramamoorthy P, Sticca R, Wagner TE, Chen WY . 2001 Int. J. Oncol. 18: 25–32

  • Reed JC . 1998 Oncogene 17: 3225–3236

  • Schorr K, Li M, Krajewski S, Reed JC, Furth PA . 1999a J. Mammary Gland Biol. Neoplasia 4: 153–164

  • Schorr K, Li M, Bar-Peled U, Lewis A, Heredia A, Lewis B, Knudson CM, Korsmeyer SJ, Jager R, Weiher H, Furth PA . 1999b Cancer Res. 59: 2541–2545

  • Shaw-Bruha CM, Pirrucello SJ, Shull JD . 1997 Breast Cancer Res. Treat. 44: 243–253

  • Topper Y, Freeman C . 1980 Physiol Rev. 60: 1049–1059

  • Vonderhaar BK . 1998 Pharmacol. Ther. 79: 169–178

  • Vonderhaar BK . 1999 Endocr. Relat. Cancer 6: 389–404

  • Wennbo H, Kindblom J, Isaksson OG, Tornell J . 1997 Endocrinology 138: 4410–4415

  • Yamauchi T, Yamauchi N, Ueki K, Sugiyama T, Waki H, Miki H, Tobe K, Matsuda S, Tsushima T, Yamamoto T, Fujita T, Taketani Y, Fukayama M, Kimura S, Yazaki Y, Nagai R, Kadowaki T . 2000 J. Biol. Chem. 275: 33937–33944

  • Yang GP, Ross DT, Kuang WW, Brown PO, Weigel RJ . 2000 Nucleic Acids Res. 27: 1517–1523

  • Yin XM, Oltvai ZN, Korsmeyer SJ . 1994 Nature 369: 321–323

  • Zhan J, Fahimi HD, Voelkl A . 1997 Biotechniques 22: 500–505

Download references

Acknowledgements

The authors wish to thank Drs Thomas Wagner and Lori Holle for their contributions to this project. We thank Ms Dianne Tinsley for her excellent clerical assistance. This work was supported in part by the Endowment Fund of the Greenville Hospital System, grants from the US Army Medical Research Command (DAMD17-99-1-9129 and DAMD17-01-1-0207) and NIH/NCI (1R21CA87093).

Author information

Authors and Affiliations

  1. Department of Microbiology and Molecular Medicine, Clemson University, Clemson, 29630, South Carolina, SC, USA

    Michael T Beck, Susan K Peirce & Wen Y Chen

  2. Oncology Research Institute, Greenville Hospital System, Greenville, 29605, South Carolina, SC, USA

    Wen Y Chen

Authors
  1. Michael T Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan K Peirce
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wen Y Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wen Y Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beck, M., Peirce, S. & Chen, W. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 21, 5047–5055 (2002). https://doi.org/10.1038/sj.onc.1205637

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205637

Keywords

This article is cited by

Search

Advanced search

Quick links